Turn Therapeutics develops topical immunomodulators for inflammatory skin diseases and other conditions, with its lead program GX-03, a non-systemic topical formulation containing polyhexanide, being evaluated for moderate-to-severe eczema and fungal nail infection. The company positions GX-03 as a non-steroidal, non-biologic alternative to injectable biologics, targeting large unmet medical needs in both the eczema and onychomycosis markets. Beyond drug development, Turn generates revenue through device licensing partnerships with established commercial entities and leverages its proprietary PermaFusion platform technology, which enables uniform delivery and stability of active ingredients, while maintaining a lean operational structure through contractor and manufacturing partnerships to maximize capital efficiency.